Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Nararak Leesakul, Keerati Kullawanichaiyanan, Sanja Mutić, Valéria Guzsvány, Tidarat Nhukeaw, Adisorn Ratanaphan, Saowanit Saithong, Takumi Konno, Uraiwan Sirimahachai & Vinich Promarak. (2021) A photoactive iridium(III) complex with 3-methyl-2-phenyl pyridine and 1,1-bis(diphenylphosphino)methane: Synthesis, structural characterization and cytotoxicity in breast cancer cells. Journal of Coordination Chemistry 74:14, pages 2380-2394.
Read now
Read now
Palma Fedele, Mariangela Ciccarese, Giammarco Surico & Saverio Cinieri. (2018) An update on first line therapies for metastatic breast cancer. Expert Opinion on Pharmacotherapy 19:3, pages 243-252.
Read now
Read now
Ting Wang, Wei Tao, Lei Zhang & Shengli Li. (2017) Oncogenic role of microRNA-20a in human multiple myeloma. OncoTargets and Therapy 10, pages 4465-4474.
Read now
Read now
Wenhui Song & Hongshun Ma. (2016) The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer. OncoTargets and Therapy 9, pages 3465-3471.
Read now
Read now
Paola Neri & Nizar J Bahlis. (2013) Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opinion on Biological Therapy 13:sup1, pages S69-S82.
Read now
Read now
Brent J. Tierney, Georgia A. McCann, David E. Cohn, Eric Eisenhauer, Meryl Sudhakar, Periannan Kuppusamy, Kálmán Hideg & Karuppaiyah Selvendiran. (2012) HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biology & Therapy 13:9, pages 766-775.
Read now
Read now
Articles from other publishers (66)
Nicoletta Staropoli, Domenico Ciliberto, Francesco Luciano, Cristina Napoli, Martina Costa, Giacomo Rossini, Mariamena Arbitrio, Caterina Labanca, Caterina Riillo, Teresa Del Giudice, Antonella Crispino, Angela Salvino, Antonio Galvano, Antonio Russo, Pierfrancesco Tassone & Pierosandro Tagliaferri. (2023) The impact of PARP inhibitors in the whole scenario of Ovarian Cancer management: a Systematic Review and Network Meta-Analysis. Critical Reviews in Oncology/Hematology, pages 104229.
Crossref
Crossref
Thitirat Temram, Ekapong Klaimanee, Saowanit Saithong, Pongsaton Amornpitoksuk, Souwalak Phongpaichit, Adisorn Ratanaphan, Yuthana Tantirungrotechai & Nararak Leesakul. (2023) Iridium(III) complexes based on cyanomethane and cyanamide ligands with luminescence quenching properties for Fe(III) sensing and biological activities. Polyhedron 243, pages 116540.
Crossref
Crossref
Anne-Marie Baird & Steven G. Gray. 2023. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
577
611
.
Brittany M. Haynes, Kristen Cunningham & Malathy P. V. Shekhar. (2022) RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage. BMC Cancer 22:1.
Crossref
Crossref
Raja Pramanik, Avinash Upadhyay, Sachin Khurana, Lalit Kumar, Prabhat S. Malik, Sunesh Kumar, M. D. Ray, S. V. S. Deo, Ritu Gupta, Deepshi Thakral, Sanjay Thulkar & V. L. Ramprasad. (2022) Comprehensive Germline Genomic Profiling of Patients with Ovarian Cancer: A Cross-Sectional Study. Indian Journal of Medical and Paediatric Oncology 43:04, pages 361-368.
Crossref
Crossref
Sajidah Jawarneh & Wamidh H. Talib. (2022) Combination of Ashwagandha Water Extract and Intermittent Fasting as a Therapy to Overcome Cisplatin Resistance in Breast Cancer: An in vitro and in vivo Study. Frontiers in Nutrition 9.
Crossref
Crossref
Nicoletta Staropoli, Mariamena Arbitrio, Angela Salvino, Francesca Scionti, Domenico Ciliberto, Rossana Ingargiola, Caterina Labanca, Giuseppe Agapito, Eleonora Iuliano, Vito Barbieri, Maria Cucè, Valeria Zuccalà, Mario Cannataro, Pierfrancesco Tassone & Pierosandro Tagliaferri. (2022) A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics. Biomedicines 10:5, pages 1210.
Crossref
Crossref
Rayhaan M. M. Ali, Stuart A. McIntosh & Kienan I. Savage. (2020) Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy. Genes, Chromosomes and Cancer 60:5, pages 358-372.
Crossref
Crossref
Daniele Caracciolo, Caterina Riillo, Maria Teresa Di Martino, Pierosandro Tagliaferri & Pierfrancesco Tassone. (2021) Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel. Cancers 13:6, pages 1392.
Crossref
Crossref
Zheling Chen, Xiao Wang, Xiao Li, Yucheng Zhou & Ke Chen. (2021) Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. Journal of International Medical Research 49:2, pages 030006052199101.
Crossref
Crossref
Vincent Ho, Liping Chung, Amandeep Singh, Vivienne Lea, Askar Abubakar, Stephanie H. Lim, Wei Chua, Weng Ng, Mark Lee, Tara L. Roberts, Paul de Souza & Cheok Soon Lee. (2020) Aberrant Expression of RAD52, Its Prognostic Impact in Rectal Cancer and Association with Poor Survival of Patients. International Journal of Molecular Sciences 21:5, pages 1768.
Crossref
Crossref
Brittany Haynes, Ambikai Gajan, Pratima Nangia-Makker & Malathy P. Shekhar. (2020) RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1866:1, pages 165561.
Crossref
Crossref
Ping Li, YanZhen Xu, Qinle Zhang, Yu Li, Wenxian Jia, Xiao Wang, Zhibin Xie, Jiayi Liu, Dong Zhao, Mengnan Shao, Suixia Chen, Nanfang Mo, Zhiwen Jiang, Liuyan Li, Run Liu, Wanying Huang, Li Chang, Siyu Chen, Hongtao Li, Wenpu Zuo, Jiaquan Li, Ruoheng Zhang & Xiaoli Yang. (2019) Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma. Cancer Cell International 19:1.
Crossref
Crossref
Tidarat Nhukeaw, Khwanjira Hongthong, Paul J. Dyson & Adisorn Ratanaphan. (2019) Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T. Apoptosis 24:7-8, pages 612-622.
Crossref
Crossref
Ainhoa Madariaga, Stephanie Lheureux & Amit Oza. (2019) Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers 11:3, pages 416.
Crossref
Crossref
Isabella Faraoni & Grazia Graziani. (2018) Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers 10:12, pages 487.
Crossref
Crossref
Yooyoung Lee, Alexandra Kollara, Taymaa May & Theodore J. Brown. (2018) Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. Journal of Ovarian Research 11:1.
Crossref
Crossref
Nicoletta Staropoli, Domenico Ciliberto, Teresa Del Giudice, Eleonora Iuliano, Maria Cucè, Francesco Grillone, Angela Salvino, Vito Barbieri, Antonio Russo, Pierfrancesco Tassone & Pierosandro Tagliaferri. (2018) The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 131, pages 83-89.
Crossref
Crossref
Marios Papadimitriou, Giannis Mountzios & Christos A. Papadimitriou. (2018) The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Cancer Treatment Reviews 67, pages 34-44.
Crossref
Crossref
Sanghamitra Mylavarapu, Asmita Das & Monideepa Roy. (2018) Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. Frontiers in Oncology 8.
Crossref
Crossref
Sergio Carrera, Aintzane Sancho, Eider Azkona, Josune Azkuna & Guillermo Lopez-Vivanco. (2017) Hereditary pancreatic cancer: related syndromes and clinical perspective. Hereditary Cancer in Clinical Practice 15:1.
Crossref
Crossref
Parichad Chuklin, Vachirawit Chalermpanaphan, Tidarat Nhukeaw, Saowanit Saithong, Kittipong Chainok, Sauwalak Phongpaichit, Adisorn Ratanaphan & Nararak Leesakul. (2017) Synthesis, X-ray structure of organometallic ruthenium (II) p-cymene complexes based on P- and N- donor ligands and their in vitro antibacterial and anticancer studies. Journal of Organometallic Chemistry 846, pages 242-250.
Crossref
Crossref
Sheng Chen, Ye Wang, Wen‑Long Zhang, Mao‑Sheng Dong & Jian‑Hua Zhang. (2017) Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer. Molecular Medicine Reports.
Crossref
Crossref
JoEllen Welsh. 2017. Animal Models for the Study of Human Disease. Animal Models for the Study of Human Disease
925
948
.
Nicoletta Staropoli, Domenico Ciliberto, Silvia Chiellino, Francesca Caglioti, Teresa Del Giudice, Simona Gualtieri, Angela Salvino, Alessandra Strangio, Cirino Botta, Sandro Pignata, Pierfrancesco Tassone & Pierosandro Tagliaferri. (2016) Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. Oncotarget 7:50.
Crossref
Crossref
Laura A Baker, Holly Holliday & Alexander Swarbrick. (2016)
ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits
BRCA1
function in basal-like breast cancer
. Endocrine-Related Cancer 23:9, pages R381-R392.
Crossref
Crossref
Mariamena Arbitrio, Maria Teresa Di Martino, Francesca Scionti, Giuseppe Agapito, Pietro Hiram Guzzi, Mario Cannataro, Pierfrancesco Tassone & Pierosandro Tagliaferri. (2016) DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. Oncotarget 7:33, pages 54028-54050.
Crossref
Crossref
Denise A. Yardley, Adam Brufsky, Robert E. Coleman, Pierfranco F. Conte, Javier Cortes, Stefan Glück, Jean-Mark A. Nabholtz, Joyce O’Shaughnessy, Robert M. Beck, Amy Ko, Markus F. Renschler, Debora Barton & Nadia Harbeck. (2015) Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 16:1.
Crossref
Crossref
MUYOU TIAN, YAHUA ZHONG, FUXIANG ZHOU, CONGHUA XIE, YUNFENG ZHOU & ZHENGKAI LIAO. (2015) Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. Molecular and Clinical Oncology 3:3, pages 720-724.
Crossref
Crossref
Nada Albarakati, Tarek M.A. Abdel-Fatah, Rachel Doherty, Roslin Russell, Devika Agarwal, Paul Moseley, Christina Perry, Arvind Arora, Nouf Alsubhi, Claire Seedhouse, Emad A. Rakha, Andrew Green, Graham Ball, Stephen Chan, Carlos Caldas, Ian O. Ellis & Srinivasan Madhusudan. (2015) Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular Oncology 9:1, pages 204-217.
Crossref
Crossref
Steven G. Gray. 2015. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
613
637
.
Tidarat Nhukeaw, Pornvichai Temboot, Kanidtha Hansongnern & Adisorn Ratanaphan. (2014) Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer 14:1.
Crossref
Crossref
Eduardo AVF Ramalho, João LQ Silva-Filho, Marina FS Cartaxo, Carmelita BL Cavalcanti, Moacyr JBM Rêgo, Maria BM Oliveira & Eduardo IC Beltrão. (2014) Assessment of changes in the brca2 and p53 genes in breast invasive ductal carcinoma in northeast Brazil. Biological Research 47:1.
Crossref
Crossref
Marzia Leotta, Lavinia Biamonte, Lavinia Raimondi, Domenica Ronchetti, Maria Teresa Di Martino, Cirino Botta, Emanuela Leone, Maria Rita Pitari, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri, Pierfrancesco Tassone & Nicola Amodio. (2014) A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells. Journal of Cellular Physiology 229:12, pages 2106-2116.
Crossref
Crossref
Athanassios Vassilopoulos, Cuiying Xiao, Cristine Chisholm, Weiping Chen, Xiaoling Xu, Tyler J. Lahusen, Carole Bewley & Chu-Xia Deng. (2014) Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors. Journal of Biological Chemistry 289:35, pages 24202-24214.
Crossref
Crossref
R Drost & J Jonkers. (2013) Opportunities and hurdles in the treatment of BRCA1-related breast cancer. Oncogene 33:29, pages 3753-3763.
Crossref
Crossref
S. Delaloge, R. Wolp-Diniz, T. Byrski, J.L. Blum, A. Gonçalves, M. Campone, P. Lardelli, C. Kahatt, A. Nieto, M. Cullell-Young & J. Lubinski. (2014) Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Annals of Oncology 25:6, pages 1152-1158.
Crossref
Crossref
O. Pinato, C. Musetti & C. Sissi. (2014) Pt-based drugs: the spotlight will be on proteins. Metallomics 6:3, pages 380-395.
Crossref
Crossref
Nicoletta Staropoli, Domenico Ciliberto, Cirino Botta, Lucia Fiorillo, Simona Gualtieri, Angela Salvino, Pierfrancesco Tassone & Pierosandro Tagliaferri. (2013) A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?. Journal of Ovarian Research 6:1.
Crossref
Crossref
Chiara Gorrini, Pegah S. Baniasadi, Isaac S. Harris, Jennifer Silvester, Satoshi Inoue, Bryan Snow, Purna A. Joshi, Andrew Wakeham, Sam D. Molyneux, Bernard Martin, Peter Bouwman, David W. Cescon, Andrew J. Elia, Zoe Winterton-Perks, Jennifer Cruickshank, Dirk Brenner, Alan Tseng, Melinda Musgrave, Hal K. Berman, Rama Khokha, Jos Jonkers, Tak W. Mak & Mona L. Gauthier. (2013) BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. Journal of Experimental Medicine 210:8, pages 1529-1544.
Crossref
Crossref
Emanuela Leone, Eugenio Morelli, Maria T. Di Martino, Nicola Amodio, Umberto Foresta, Annamaria Gullà, Marco Rossi, Antonino Neri, Antonio Giordano, Nikhil C. Munshi, Kenneth C. Anderson, Pierosandro Tagliaferri & Pierfrancesco Tassone. (2013)
Targeting miR-21 Inhibits
In Vitro
and
In Vivo
Multiple Myeloma Cell Growth
. Clinical Cancer Research 19:8, pages 2096-2106.
Crossref
Crossref
Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio, Marta Lionetti, Emanuela Leone, Nicola Amodio, Pietro Hiram Guzzi, Umberto Foresta, Francesco Conforti, Mario Cannataro, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri & Pierfrancesco Tassone. (2013) In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma. Oncotarget 4:2, pages 242-255.
Crossref
Crossref
Nicoletta Staropoli, Cirino Botta, Domenico Ciliberto, Lucia Fiorillo, Antonina Maria De Angelis, Caterina Viscomi, Simona Gualtieri, Angela Salvino, Pierfrancesco Tassone & Pierosandro Tagliaferri. (2013) Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice. Journal of Cancer Therapy 04:05, pages 1005-1017.
Crossref
Crossref
JoEllen Welsh. 2013. Animal Models for the Study of Human Disease. Animal Models for the Study of Human Disease
997
1018
.
Haim Werner & Ilan Bruchim. (2012) IGF-1 and BRCA1 signalling pathways in familial cancer. The Lancet Oncology 13:12, pages e537-e544.
Crossref
Crossref
Ting-Yan Shi, Gong Yang, Xiao-Yu Tu, Jing-Min Yang, Ji Qian, Xiao-Hua Wu, Xiao-Yan Zhou, Xi Cheng & Qingyi Wei. (2012) RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer. PLoS ONE 7:11, pages e50461.
Crossref
Crossref
N Amodio, M T Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, A M Gullà, M R Pitari, F Conforti, M Rossi, V Agosti, M Fulciniti, G Misso, F Morabito, M Ferrarini, A Neri, M Caraglia, N C Munshi, K C Anderson, P Tagliaferri & P Tassone. (2012) miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death & Disease 3:11, pages e436-e436.
Crossref
Crossref
Nicola Amodio, Marzia Leotta, Dina Bellizzi, Maria Teresa Di Martino, Patrizia D’Aquila, Marta Lionetti, Fernanda Fabiani, Emanuela Leone, Anna Maria Gullà, Giuseppe Passarino, Michele Caraglia, Massimo Negrini, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri & Pierfrancesco Tassone. (2012) DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 3:10, pages 1246-1258.
Crossref
Crossref
Hanmanth J.R. Neboori, Bruce G. Haffty, Hao Wu, Qifeng Yang, Amal Aly, Sharad Goyal, Devora Schiff, Meena S. Moran, Ryan Golhar, Chunxia Chen, Dirk Moore & Shridar Ganesan. (2012) Low p53 Binding Protein 1 (53BP1) Expression Is Associated With Increased Local Recurrence in Breast Cancer Patients Treated With Breast-Conserving Surgery and Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 83:5, pages e677-e683.
Crossref
Crossref
Sook Ryun Park & Alice Chen. (2012) Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment. Hematology/Oncology Clinics of North America 26:3, pages 649-670.
Crossref
Crossref
Jessica N McAlpine, Henry Porter, Martin Köbel, Brad H Nelson, Leah M Prentice, Steve E Kalloger, Janine Senz, Katy Milne, Jiarui Ding, Sohrab P Shah, David G Huntsman & C Blake Gilks. (2012) BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Modern Pathology 25:5, pages 740-750.
Crossref
Crossref
Evgeny N Imyanitov & Vladimir M Moiseyenko. (2011) Drug therapy for hereditary cancers. Hereditary Cancer in Clinical Practice 9:1.
Crossref
Crossref
Chiara Arienti, Anna Tesei, Giorgio Maria Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori & Wainer Zoli. (2011) Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. Journal of Translational Medicine 9:1.
Crossref
Crossref
Wei Zhang & Yingyan Yu. (2011) The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer. International Journal of Molecular Sciences 12:9, pages 5672-5683.
Crossref
Crossref
Christoforos G. Thomas, Anders Strom, Karolina Lindberg & Jan-Ake Gustafsson. (2010) Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling. Breast Cancer Research and Treatment 127:2, pages 417-427.
Crossref
Crossref
Kenneth J. O’Byrne, Martin P. Barr & Steven G. Gray. (2011) The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers 3:1, pages 1426-1453.
Crossref
Crossref
Apichart Atipairin, Bhutorn Canyuk & Adisorn Ratanaphan. (2010) The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Research and Treatment 126:1, pages 203-209.
Crossref
Crossref
Apichart AtipairinAdisorn Ratanaphan. (2011) In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer: Basic and Clinical Research 5, pages BCBCR.S8184.
Crossref
Crossref
Dokyung KimWoohee JungJa Seung Koo. (2011) The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes. Journal of Korean Medical Science 26:3, pages 352.
Crossref
Crossref
Brian M. Alexander, Kam Sprott, D. Allan Farrow, XiaoZhe Wang, Alan D. D'Andrea, Stuart J. Schnitt, Laura C. Collins, David T. Weaver & Judy E. Garber. (2010) DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer. Clinical Cancer Research 16:23, pages 5796-5804.
Crossref
Crossref
Steven A. Narod. (2010) BRCA mutations in the management of breast cancer: the state of the art. Nature Reviews Clinical Oncology 7:12, pages 702-707.
Crossref
Crossref
Melissa Price & Alvaro N.A. Monteiro. (2010) Fine tuning chemotherapy to match BRCA1 status. Biochemical Pharmacology 80:5, pages 647-653.
Crossref
Crossref
A. A. Rodriguez, A. Makris, M. F. Wu, M. Rimawi, A. Froehlich, B. Dave, S. G. Hilsenbeck, G. C. Chamness, M. T. Lewis, L. E. Dobrolecki, D. Jain, S. Sahoo, C. K. Osborne & J. C. Chang. (2010) DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Research and Treatment 123:1, pages 189-196.
Crossref
Crossref
Apichart Atipairin, Bhutorn Canyuk & Adisorn Ratanaphan. (2010) Cisplatin Affects the Conformation of Apo Form, not Holo Form, of BRCA1 RING Finger Domain and Confers Thermal Stability. Chemistry & Biodiversity 7:8, pages 1949-1967.
Crossref
Crossref
Carly St. Germain, Nima Niknejad, Laurie Ma, Kyla Garbuio, Tsonwin Hai & Jim Dimitroulakos. (2010) Cisplatin Induces Cytotoxicity through the Mitogen-Activated Protein Kinase Pathways ana Activating Transcription Factor 3. Neoplasia 12:7, pages 527-538.
Crossref
Crossref
Zbigniew Darzynkiewicz, Frank Traganos & Donald Wlodkowic. (2009) Impaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. European Journal of Pharmacology 625:1-3, pages 143-150.
Crossref
Crossref